{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:01:57Z","timestamp":1791655317166,"version":"4.3.4"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biologicals.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:49:03Z","timestamp":1597477743000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues"],"prefix":"10.1016","volume":"67","author":[{"given":"Marc","family":"Baay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Neels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2020.08.006_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biologicals.2020.06.005","article-title":"SARS-CoV-2: virology, epidemiology, immunology and vaccine development","volume":"66","author":"Baay","year":"2020","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2020.08.006_bib2","first-page":"53","volume":"66","author":"Bekeredjian-Ding","year":"2020"},{"key":"10.1016\/j.biologicals.2020.08.006_bib3","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1038\/srep11451","article-title":"Genetic drift of human coronavirus OC43 spike gene during adaptive evolution","volume":"5","author":"Ren","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.biologicals.2020.08.006_bib4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2020.08.006_bib6","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S1473-3099(20)30438-2","article-title":"COVID-19 human challenge studies: ethical issues","volume":"20","author":"Jamrozik","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2020.08.006_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1126\/science.abc1076","article-title":"Ethics of controlled human infection to address COVID-19","volume":"368","author":"Shah","year":"2020","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.biologicals.2020.08.006_bib8","article-title":"Genomewide association study of severe covid-19 with respiratory failure","author":"Ellinghaus","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:15:17Z","timestamp":1760922917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105620300968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":7,"alternative-id":["S1045105620300968"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.08.006","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}